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Abstract An auto-inflammatory syndrome consequent to
SAMHD1 mutations involves cerebral vasculopathy char-
acterized by multifocal stenosis and aneurysms within
large arteries, moyamoya, chronic ischemia, and early-
onset strokes (SAMS). While this condition involves the
innate immune system, additional clinical features mimic
systemic lupus erythematosus. Mutations in this gene can
also cause a subset of the rare genetic condition Aicardi-
Goutières syndrome. To date, no established therapy suc-
cessfully prevents disease progression. We report a
corticosteroid-dependent SAMS patient, a 19-year-old
male of Old Order Amish ancestry, with diffuse cerebral
arteriopathy identified through contrast brain magnetic res-
onance arteriography (MRA) and MRI. He received sub-
cutaneous adalimumab every 2 weeks for 9 months with
minimal response. Then, he started intravenous tocilizumab
(6 mg/kg/dose) every 4 weeks. He sustained steadily normal-
izing cerebral vasculopathy and lab abnormalities resolved,
allowing prednisone reduction. We conclude that the cerebral
vasculopathy of the homozygous SAMHD1 mutation-
mediated auto-inflammatory disease SAMS responded favor-
ably to tocilizumab infusion therapy.
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Introduction
Cerebral vasculopathy associated with mutations in the
SAMHD1 gene can invoke early-onset stroke [1]. Mutations
in this gene can also cause the rare genetic condition, Aicardi-
Goutières syndrome (AGS, MIM225750), which bears a phe-
notypic resemblance to this cerebral vasculopathy occurring
in the Amish population. AGS involves increased production
of interferon (IFN)-α2 [2]. Loss-of-function mutations in any
of six IFN-stimulated genes (TREX1, RNASEH2A,
RNASEH2B, RNASEH2C, SAMHD1, and ADAR) are the
identified cause of AGS [3]. These mutations involve the in-
nate rather than the adaptive immune system. AGS presents
with a phenotypic overlap of early-onset encephalopathy,
mimicking congenital viral infection (cerebrospinal fluid lym-
phocytosis and elevated IFN-α levels, loss of white matter,
and basal ganglia calcifications), and features of systemic lu-
pus erythematosus (SLE), including cytopenias, oral ulcers,
arthritis, perniosis with cutaneous erythematous lesions, and
autoantibodies [4, 5]. AGS can involve a subset of children
that develop early-onset SLE [5]. Intracerebral large artery
disease and chronic progressive arthropathy with distal joint
contractures have been reported in AGS associated with mu-
tation of AGS5 SAMHD1 protein [6, 7]. Further, AGS associ-
ated with heterozygous TREX1 mutations involves ulcerating
acral skin lesions suggestive of chilblain lupus (lupus pernio)
[8]. Heterozygous SAMHD1 mutation can also be associated
with progressive arthropathy, distal joint contractures, painful
oral ulcers, and chilblains [9].
We describe a patient with a similar clinical spectrum who
does not have AGS, rather homozygous SAMHD1 mutation
which led to cerebral vasculopathy. Affected patients within
described pedigrees carrying this mutation develop multifocal
cerebral stenosis and aneurysms within large arteries, chronic
ischemic changes and moyamoya morphology, leading to
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early-onset strokes [1]. We report the first successful reversal
of this cerebral vasculopathy with tocilizumab infusion
therapy.
Case report
The 19-year-old male patient MM, of Old Order Amish an-
cestry, was previously reported with autosomal recessive ho-
mozygous SAMHD1mutation (X-28 in the original study) [1].
Briefly, he developed symmetric Bdry^ polyarthritis at age
9 years, hoarseness at age 12 years requiring vocal nodule
resection, bilateral hand and foot pernio at age 13 years, and
a clinical course characterized by familial short stature, pho-
tosensitivity, and persistent acral vasculopathy presenting as
episodic Raynaud’s disease and progressive, bilateral hand
and foot sclerodactyly. Peripheral vascular examination re-
vealed diminished bilateral carotid Korotkoff sounds, without
bruits of his bilateral carotid or subclavian arteries, or abdom-
inal aorta. Table 1 summarizes salient data from his disease
and treatment course.
MM underwent contrast brain magnetic resonance arteri-
ography (MRA) and contrast brain MR imaging (MRI) based
upon familial risk associated with his sister’s encephalopathy
and the desire to identify potential vasculopathy prior to sim-
ilarly devastating functional consequences. MM’s initial stud-
ies performed at age 16 years were abnormal. On MRA, he
had diffuse narrowing of his bilateral internal carotid arteries
and irregular, narrowed segments of his bilateral anterior ce-
rebral arteries’ A1 and M1 segments (Fig. 1, 1A–C). His bi-
lateral thalamostriate vessels had increased flow, with mild
asymmetry in the early arterial phase of the perfusion study,
consistent with a compensated perfusion pattern despite ex-
tensive fibromuscular changes of arteriopathy. His brain MRI
had no evidence of cerebrovascular occlusive disease; howev-
er, he had bilateral, diffuse arteriopathic changes of his distal
internal carotid, anterior, and middle cerebral arteries. Figure 1
depicts the serial contrast cerebral MRA findings during his
treatment course. Figure 2 depicts the temporal sequence of
MM’s medication interventions.
Based upon adalimumab’s capacity to penetrate the central
nervous system’s blood brain barrier and the putatively pro-
tective role of functional SAMDH1 in mediating the pro-
inflammatory tumor necrosis factor (TNF)-α response [1],
MM started 40 mg SC adalimumab every other week just
prior to obtaining an interval brain MRI/MRA. MM
underwent serial, biannual, contrast brain imaging (MRI and
MRA) including 3D time-of-flight MRA of the circle of
Willis, to assess therapeutic efficacy, and accompanying lab-
oratory biomarkers of inflammation: erythrocyte sedimenta-
tion rate (ESR), Immunoglobulin G (IgG) and total protein.
Throughout his pre-biologic or biologic therapy clinical
course, the C-reactive protein never increased, nor did he
manifest anemia of chronic disease.
Compared to his baseline study (month 0), contrast brain
MRI and MRA obtained at onset of adalimumab therapy
Table 1 Data summary
Elapsed time 6/10/09 8/15/11 1/6/12 5/18/12 7/13/12 8/9/12 11/1/12 1/24/13 5/23/13
Years 0 2.2 0.4 0.3 0.2 0.1 0.2 0.2 0.3
Months 0 26 4.8 4.1 1.9 0.9 2.8 2.8 4
Cumulative (months) 0 26 30.8 34.9 36.8 37.7 40.5 43.3 47.3
Medication (mg/dose)
Methotrexate (oral, weekly) 20 0 0 0 0 0 0 0 0
Prednisone (oral, daily) 5 10 10 10 60 30 20 10 0
Adalimumab (SC every 2 weeks) 0 40 40 40 0 0 0 0 0
Tocilizumab (monthly infusion number) 0 0 0 0 400 (2nd) 400 (3rd) 400 (6th) 400 (8th) 400 (12th)
Lab results (range)
Hemoglobin (130–160 g/L) 14.2 159 158 153 140 155 150 144 146
ESR (0–15 mm/h) 27 10 18 47 14 10 10 10 7
Immunoglobulin G (7.24–16.11 g/L) 19.30 18.70 ND 17.20 ND ND ND 13.90 ND
Total protein (63–82 g/L) ND 85 90 91 78 85a 84 76 78
Platelets (135–466 × 109/L) 308 248 248 313 232 250 257 253 226
Interleukin-6 (0–0.238 pmol/L) 0.571 1.14
Joint count
Active joints 17 0 0 0 0 0 0
Limited joints 29 22 20 20 20 20 17
ND no data
a 7/20/12 total protein
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(month 26) indicated a mixed picture. Vasculopathy
progressed with mild narrowing of his vertebral arteries’ distal
segments and bilateral globus pallidus early collateralization
consistent with moyamoya. Cerebrovascular disease remained
unchanged with persistent bilateral distal internal carotid ar-
tery narrowing and indicated mild improvement of the anterior
cerebral A1 segments and proximal middle cerebral arteries
(M1 segments). There were equivocal changes of mild basilar
artery narrowing and subtle abnormalities of the internal cap-
sules’ posterior limb (arising from the anterior cerebral A1 and
M1 segments). There was also increased signal intensity of the
corticospinal tracts, extending into his cerebral peduncles and
pons. The second study obtained during adalimumab therapy at
month 31 indicated stable vasculopathy without progressive
change in these previously identified abnormalities (Fig. 1, 2A–C).
During a 9-month course of adalimumab therapy, there was
mild evidence of disease advancement (including evolving
moyomoya) but predominant stability while he remained on
a daily 10-mg prednisone dose. However, the therapeutic goal
was amelioration of identified extra- and intracranial medium-
and small-vessel vasculitis with elimination of corticosteroid
dependence. Failure to meet these goals compelled the deci-
sion to change biologic therapy. Serum interleukin-6 (IL-6)
was elevated (0.571 pmol/L) [normal 0–0.238] after 9 months
of adalimumab therapy. With this evidence, he discontinued
adalimumab at month 35 and started tocilizumab 400 mg IV
every 4 weeks at month 36 (6.2 mg/kg/dose).
Although MM did not appreciate a clinical change in
his perniosis or articular disease after his first two month-
ly tocilizumab infusions, he had appreciable improvement
Fig. 1 Serial contrast magnetic resonance cerebral arteriography
Fig. 2 Treatment course
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in his cerebral vasculopathy. This coincided with temporal
deterioration in unilateral hand perniosis requiring escala-
tion in his prednisone dose to 1 mg/kg/day during his
second month of tocilizumab therapy. He tapered predni-
sone successfully to 0.5 mg/kg/day by his third monthly
infusion, when he obtained repeat brain imaging.
Following two tocilizumab infusions, the MRA at month
38 indicated similarly stable findings with the exception
of normalization of his A1 and M1 cerebral artery seg-
ments (Fig. 1, 3A–C). At month 43, the second MRA
obtained during tocilizumab therapy indicated stable in-
creased signal intensity within the bilateral internal cap-
sules’ posterior limbs; other previous abnormalities
remained stable, and the A1 and M1 cerebral artery seg-
ments stayed normal (Fig. 1, 4A–C). At month 47, repeat
MRA following 11 consecutive tocilizumab infusions re-
vealed stable, bilateral distal internal carotid artery
narrowing, continued A1 and M1 segment improvement,
resolution of globus pallidus communicating artery
collateralization (moyamoya), and normalization of the
previously increased bilateral cortical spinal tract signal
intensity (Fig. 1, 5A–C).
Discussion
The auto-inflammatory disease SAMS, an acronym for
cerebral stenosis, aneurysm, moyomoya, and stroke, pro-
duces a heterogeneous phenotype of diverse clinical pre-
sentations, including cerebral palsy, stroke, developmental
delay, failure to thrive, chilblains, and arthritis. Early fea-
tures include mild intrauterine growth restriction, infantile
hypotonia, and irritability, followed by failure to thrive
and short stature. During cold weather months, affected
patients experience a spectrum of vascular abnormalities
of their acral regions including Raynaud’s disease and
chilblain lesions (lupus pernio). They may also have a
low-pitch hoarse voice, glaucoma, migraine headache,
and arthritis characterized by joint tenderness and restrict-
ed motion. Patients do not have hypertension; their car-
diopulmonary, hepatic, and renal function is normal. The
elevated ESR, IgG, neopterin, and tumor necrosis factor-α
(TNF-α) found in these patients are consistent with in-
flammatory disease. Cerebral vasculopathy is a major
hallmark found in all affected individuals typified by ste-
noses and aneurysms. Distinctive neuroimaging findings
include chronic ischemic changes, multifocal stenoses of
the large intracranial arteries, including some with
moyamoya morphology and evidence of prior acute in-
farction and hemorrhage [1]. Clinical outcomes in affected
patients are largely dependent on cerebral vasculopathic pro-
gression. Indeed, the early-onset or recurrence of cerebral
vasculopathy-associated strokes always predicts severe func-
tional impairment and poor cognitive outcomes.
While the specific pathophysiology is uncertain, aberrant
processes involving the innate immune system may support
one or several potential mechanisms. Defective metabolism of
intracellular nucleic acids can activate a cell-intrinsic autoim-
mune response, pivotal to host capacity to discriminate be-
tween self and non-self (e.g., viral) nucleic acids. Nucleic acid
recognition is an essential innate immune strategy for detect-
ing viral infection. Functional regulation involves prevention
of self-activated innate immunity, including negative regula-
tion of the IFN-stimulatory DNA (ISD) response. Virtually all
IFN-mediated antiviral immunity occurs via two types of
nucleic acid detection systems: toll-like receptors (TLRs)
and cytosolic sensors [10]. Because flawed distinction of viral
from self nucleic acids can occur, defective clearance of self-
derived nucleic acids may lead to severe, IFN-associated au-
toimmunity [11]. Activation of TLRs on autoreactive B cell
lymphocytes is a major contributing mechanism. Specific
TLRs predispose to autoantibody production in murine
models of lupus and autoimmunity. Such activation of TLR-
dependent IFN production also occurs in human autoimmuni-
ty (e.g., psoriasis) [12]. In each circumstance, accumulated
nucleic acids are detected by non-cell autonomous mecha-
nisms rather than cell-dependent detection [11].
Cytosolic nucleic acid sensors can initiate autoimmunity if
flawed control mechanisms exist. Negative regulators of the
ISD response play a major role in preventing self-activation of
innate immunity via cell-intrinsic components. One important
negative regulatory mechanism in part involves 3′ repair exo-
nuclease 1 (TREX1) induction. TREX1 is a cytosolic toll-like
receptor-independent, antiviral pathway that detects DNA and
triggers immune activation through transcription factor IFN
regulatory factor 3 [11]. Cell-intrinsic initiation of autoimmu-
nity has distinct requirements for regulation and unique mech-
anisms that precipitate lymphocyte-dependent autoimmunity.
Autoimmunity may be triggered by cell-intrinsic initiation of
the ISD pathway in TREX1-deficient mice, preceding a TLR-
dependent contribution to autoantibody production [11].
Disease pathogenesis may reflect SAMHD1 protein loss of
function instead of partially functional protein expression [1].
The SAMHD1 gene mutation localizes to chromosome
20q11.22-q12 involving a pathogenic, homozygous splice-
acceptor site mutation (c.1411–2A > G) in intron 12. The
SAMHD1 gene consists of 16 coding exons and encodes a
protein of 626 amino acids. This identified mutation results
in exon 13mRNA transcription skipping, leading to formation
of an aberrant protein. There are two functional domains in the
SAMHD1 protein: a sterile alpha motif (SAM) (residuals 42–
110) and an HD domain (residuals 160–325) [1]. The SAM
domain has the ability to bind RNA [13]. The HD domain
recurs in an enzyme superfamily with phosphohydrolase ac-
tivity which is involved in nucleic acid metabolism [14].
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SAMHD1 is a dGTP-stimulated triphosphohydrolase; it con-
ver t s deoxynucleos ide t r iphospha tes (dNTP) to
deoxynucleoside and inorganic triphosphate. This gene de-
creases dNTP to minimal levels that do not support reverse
transcription, preventing viral infection [15, 16]. SAMHD1
also plays a significant role in clearance of cellular waste
and maintaining IFN homeostasis [2]. While this suggests
SAMHD1 may function as a nuclease, SAMHD1, like
TREX1, is also another potential negative regulator of the
ISD response. Both genes may have a similarly protective,
immunomodulatory role in preventing self-activation of in-
nate immunity. Finally, SAMHD1 may further provide a
protective role in mediating TNF-α pro-inflammatory
responses [2].
In a case-control study of AGS, a phenotypically similar
inflammatory disorder caused by mutations in any of six IFN-
stimulating genes (SAMHD1, TREX1 , RNASEH2A,
RNASEH2B, RNASEH2C and ADAR), 90% (74/82) of affect-
ed patients vs. 7% (2/29) of controls had a positive IFN score,
reflecting increased expression of these genes [3]. Clinically,
AGS presents as an infantile encephalopathy, manifesting as
progressive microcephaly and psychomotor retardation; 25%
of patients die in early childhood consequent to its leukodys-
trophy and microangiopathy. A leading hypothesis regarding
AGS is that the accumulation of intracellular nucleic acids
triggers an auto-inflammatory response and consequent in-
creased astrocytic IFN-α production [17]. In AGS, chronic
IFN-α exposure results in altered gene expression for proteins
involved in the stability of brain white matter (ATF4, eIF2Bα,
cathepsin D, cystatin F), an increase of antigen-presenting
genes (human leukocyte antigen class I) and downregulation
of pro-angiogenic factors and other cytokines, i.e., vascular
endothelial growth factor and interleukin-1 (IL-1). These ef-
fects on therapeutic targets for AGS and other IFN-α-
mediated encephalopathies, may primarily involve down-
stream IFN-α signaling cascade effectors rather than only
IFN-α [17].
The relationship of increased IL-6 production and IFN-α
signaling in the context of SAMHD1 mutation disease is un-
clear. However, the model of viral infection provides context
for indirect evidence of increased IL-6 expression consequent
to IFN-α priming. During viral infection, host cells are alerted
by the presence of circulating class I IFN, preparing them for
response if they become infected. When a cell recognizes
double-stranded RNA (dsRNA), this indicates the cell is likely
already infected with virus. However, when a cell encounters
either IL-1β or TNF-α, the cell receives warning about the
host’s escalating inflammatory response. This warning does
not indicate direct viral infection of the cell. Instead, the class I
IFN priming phenomenon promotes a vigorous response to
direct viral infection more than IL-1β or TNF-α provide.
While IFN-α does not directly induce IL-6 expression, prior
cellular exposure to IFN-α synergistically enhances IL-6
expression in response to the viral dsRNA. The magnitude
and kinetics of IL-6 induction vary in these situations since
class I IFNs selectively enhance response to dsRNA [18].
Systemic vasculitides with increased IL-6 expression in-
clude Takayasu’s arteritis [19–22], acute Henoch-Schönlein
purpura [23], giant cell arteritis [24, 25], acute Kawasaki dis-
ease [26–28], and various large vessel vasculitides [29–33].
Tocilizumab therapy provides a promising role in achieving
disease remission for refractory neuro-Behçet’s disease, re-
lapsing or refractory giant cell arteritis, and large vessel vas-
culitis secondary to Takayasu’s arteritis, Cogan syndrome, and
relapsing polychondritis [29, 33–39].
TNF inhibition (typically infliximab) has circumstantial
evidence suggesting efficacy in open label use for large vessel
vasculitis secondary to refractory Takayasu’s arteritis, relaps-
ing polychondritis, Behçet’s disease (also including
adalimumab), and relapsing polychondritis. However, this ap-
proach has not been effective for large vessel vasculitis due to
giant cell arteritis as demonstrated in randomized controlled
trials or a prospective trial for granulomatosis with polyangi-
itis [31, 40]. Adalimumab stabilized our patient’s cerebral
vasculitis without remarkably reversing progressive
arteriopathy.
Results are mixed regarding the efficacy of TNF inhibitors
for the therapy of lupus pernio. TNF inhibitors can induce this
disease [41]. However, lupus pernio secondary to sarcoidosis
responded swiftly to adalimumab in one case report [42].
Tocilizumab has not been reported for this use. Neither
adalimumab nor tocilizumab were effective for our patient’s
SAMS-associated pernio.
Conclusions
There is no established, uniformly successful treatment strat-
egy for SAMS, an auto-inflammatory disease consequent to
homozygous SAMHD1 mutation. Relapses remain common
with prednisone tapering. Traditional corticosteroid-sparing,
non-biologic immunosuppressive medications used in the
treatment of rheumatic diseases involving adaptive immunity,
e.g., methotrexate, are ineffective in the treatment of SAMS
cerebral vasculopathy, a disease involving the innate immune
system. Based on the effectiveness of tocilizumab in control-
ling a variety of active large vessel vasculitides including
Takayasu’s arteritis and giant cell arteritis, tocilizumab pro-
vides a novel therapeutic option for SAMS. Following its
initiation, MM obtained disease control within 2 months,
followed by substantial reversal of much of his cerebral vas-
culopathy after nearly a year of tocilizumab treatment. With
this apparent efficacy and durability, tocilizumab may offer a




Compliance with ethical standards
Funding source No funding was secured for this study.
Financial disclosure Authors have no financial relationships relevant
to this article to disclose.
Disclosures None.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Xin B, Jones S, Puffenberger EG, Hinze C, Bright A, Tan H, Zhou
A, Wu G, Vargus-Adams J, Agamanolis D, Wang H (2011)
Homozygous mutation in SAMHD1 gene causes cerebral vasculop-
athy and early onset stroke. Proc Natl Acad Sci U S A 108:5372–
5377. doi:10.1073/pnas.1014265108
2. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM,
Fuller JC, Jackson RM, Lamb T, Briggs TA, Ali M, Gornall H,
Couthard LR, Aeby A, Attard-Montalto SP, Bertini E, Bodemer
C, Brockmann K, Brueton LA, Corry PC, Desguerre I, Fazzi E,
Cazorla AG, Gener B, Hamel BC, Heiberg A, Hunter M, van der
Knaap MS, Kumar R, Lagae L, Landrieu PG, Lourenco CM,
Marom D, McDermott MF, van der Merwe W, Orcesi S,
Prendiville JS, Rasmussen M, Shalev SA, Soler DM, Shinawi M,
Spiegel R, Tan TY, Vanderver A, Wakeling EL, Wassmer E,
Whittaker E, Lebon P, Stetson DB, Bonthron DT, Crow YJ
(2009) Mutations involved in Aicardi-Goutières syndrome impli-
cate SAMHD1 as regulator of the innate immune response. Nat
Genet 41:829–832. doi:10.1038/ng.373
3. Rice GI, Forte GM, Szynkiewicz M, Chase DS, Aeby A, Abdel-
Hamid MS, Ackroyd S, Allcock R, Bailey KM, Balottin U,
Barnerias C, Bernard G, Bodemer C, Botella MP, Cereda C,
Chandler KE, Dabydeen L, Dale RC, De Laet C, De Goede CG,
Del Toro M, Effat L, Enamorado NN, Fazzi E, Gener B, Haldre M,
Lin JP, Livingston JH, Lourenco CM, Marques W Jr, Oades P,
Peterson P, Rasmussen M, Roubertie A, Schmidt JL, Shalev SA,
Simon R, Spiegel R, Swoboda KJ, Temtamy SA, Vassallo G, Vilain
CN, Vogt J, Wermenbol V, Whitehouse WP, Soler D, Olivieri I,
Orcesi S, Aglan MS, Zaki MS, Abdel-Salam GM, Vanderver A,
Kisand K, Rozenberg F, Lebon P, Crow YJ (2013) Assessment of
interferon-related biomarkers in Aicardi-Goutières syndrome asso-
ciated with mutations in TREX1, RNASEH2A, RNASEH2B,
RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet
Neurol 12:1159–1169. doi:10.1016/S1474-4422(13)70258-8
4. Crow YJ, Rehwinkel J (2009) Aicardi-Goutières syndrome and
related phenotypes: linking nucleic acid metabolism with autoim-
munity. HumMol Genet 18:R130–R136. doi:10.1093/hmg/ddp293
5. Ramantani G, Kohlhase J, Hertzberg C, Innes AM, Engel K,
Hunger S, Borozdin W, Mah JK, Ungerath K, Walkenhorst H,
Richardt HH, Buckard J, Bevot A, Siegel C, von Stülpnagel C,
Ikonomidou C, Thomas K, Proud V, Niemann F, Wieczorek D,
Häusler M, Niggemann P, Baltaci V, Conrad K, Lebon P, Lee-
Kirsch MA (2010) Expanding the phenotypic spectrum of lupus
erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum
62:1469–1477. doi:10.1002/art.27367
6. Dale RC, Gornall H, Singh-Grewal D, Alcausin M, Rice GI, Crow
YJ (2010) Familial Aicardi-Goutières syndrome due to SAMHD1
mutations is associated with chronic arthropathy and contractures.
Am J Med Genet A 152A:938–942. doi:10.1002/ajmg.a.33359
7. Ramesh V, Bernardi B, Stafa A, Garone C, Franzoni E, Abinun M,
Mitchell P, Mitra D, Friswell M, Nelson J, Shalev SA, Rice GI,
Gornall H, Szynkiewicz M, Aymard F, Ganesan V, Prendiville J,
Livingston JH, Crow YJ (2010) Intracerebral large artery disease in
Aicardi-Goutières syndrome implicates SAMHD1 in vascular ho-
meostasis. Dev Med Child Neurol 52:725–732. doi:10.1111/j.
1469-8749.2010.03727.x
8. Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K,
Robins P, Harvey S, Hollis T, O'Hara A, Herrick AL, Bowden
AP, Perrino FW, Lindahl T, Barnes DE, Crow YJ (2007)
Heterozygous mutations in TREX1 cause familial chilblain lupus
and dominant Aicardi-Goutières syndrome. Am J Hum Genet 80:
811–815. doi:10.1086/513443
9. Ravenscroft JC, Suri M, Rice GI, Szynkiewicz M, Crow YJ (2011)
Autosomal dominant inheritance of a heterozygous mutation in
SAMHD1 causing familial chilblain lupus. Am J Med Genet A
155A:235–237. doi:10.1002/ajmg.a.33778
10. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S,
Kawai T, Akira S (2007) Differential role of TLR- and RLR-
signaling in the immune responses to influenza A virus infection
and vaccination. J Immunol 179:4711–4720
11. Stetson DB, Ko JS, Heidmann T, Medzhitov R (2008) Trex1 pre-
vents cell-intrinsic initiation of autoimmunity. Cell 134:587–598.
doi:10.1016/j.cell.2008.06.032
12. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH,
Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I,
Schröder JM, Liu YJ, Gilliet M (2007) Plasmacytoid dendritic cells
sense self-DNA coupled with antimicrobial peptide. Nature 449:
564–569. doi:10.1038/nature06116
13. Kim CA, Bowie JU (2003) SAM domains: uniform structure,
diversity of function. Trends Biochem Sci 28:625–628. doi:
10.1016/j.tibs.2003.11.001
14. Aravind L, Koonin EV (1998) The HD domain defines a new
superfamily of metal-dependent phosphohydrolases. Trends
Biochem Sci 23:469–472
15. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC,
Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF,
Yap MW, de Carvalho LP, Stoye JP, Crow YJ, Taylor IA,
Webb M (2011) HIV-1 restriction factor SAMHD1 is a
deoxynucleoside triphosphate triphosphohydrolase. Nature
480:379–382. doi:10.1038/nature10623
16. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC,
Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino
G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau
NR, Kim B, Margottin-Goguet F (2011) SAMHD1 restricts the
replication of human immunodeficiency virus type 1 by depleting
the intracellular pool of deoxynucleoside triphosphates. Nat
Immunol 13:223–228. doi:10.1038/ni.2236
17. Cuadrado E, Jansen MH, Anink J, De Filippis L, Vescovi AL,
Watts C, Aronica E, Hol EM, Kuijpers TW (2013) Chronic
exposure of astrocytes to interferon-α reveals molecular
changes related to Aicardi-Goutieres syndrome. Brain 136:
245–258. doi:10.1093/brain/aws321
18. Harcourt JL, Offermann MK (2000) Interferon-alpha synergistical-
ly enhances induction of interleukin-6 by double stranded RNA in
HeLa cells. Eur J Biochem 267:2768–2777
19. SunY,MaL, Yan F, LiuH, DingY, Hou J, Jiang L (2012)MMP-9 and
IL-6 are potential biomarkers for disease activity in Takayasu’s arteritis.
Int J Cardiol 156:236–238. doi:10.1016/j.ijcard.2012.01.035
Clin Rheumatol
20. Cayci FS, Ekim M, Egin Y, Gökce H, Yalcinkaya F, Ozcakar B,
Akar N (2013) An analysis of the levels of the soluble form of the
endothelial protein C receptor in children with Henoch-Schönlein
purpura. Pediatr Hematol Oncol 32:115–122. doi:10.3109/
08880018.2013.860648
21. Clifford A, Hoffman GS (2014) Recent advances in the medical
management of Takayasu arteritis: an update on use of biologic
therapies. Curr Opin Rheumatol 26:7–15. doi:10.1097/BOR.
0000000000000004
22. Keser G, Direskeneli H, Aksu K (2014) Management of Takayasu
arteritis: a systematic review. Rheumatology (Oxford) 53:793–801.
doi:10.1093/rheumatology/ket320
23. Lin CY, Yang YH, Lee CC, Huang CL, Wang LC, Chiang BL
(2006) Thrombopoietin and interleukin-6 levels in Henoch-
Schönlein purpura. J Microbiol Immunol Infect 39:476–482
24. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M,
García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-
Márquez A, Palacín A, Colomer D, Cid MC (2004) Tissue produc-
tion of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6)
correlates with the intensity of the systemic inflammatory response
and with corticosteroid requirements in giant-cell arteritis.
Rheumatology (Oxford) 43:294–301. doi:10.1093/rheumatology/
keh058
25. Emilie D, Liozon E, Crevon MC, Lavignac C, Portier A, Liozon F,
Galanaud P (1994) Production of interleukin 6 by granulomas of
giant cell arteritis. Hum Immunol 39:17–24
26. Abe J, Matsuda A (2013) Biomarkers associated with unrespon-
siveness to IVIG in children with Kawasaki disease. Nihon
Rinsho Meneki Gakkai Kaishi 36:27–34
27. Ge X, Li CR, Yang J, Wang GB (2013) Aberrantly decreased levels
of NKG2D expression in children with Kawasaki disease. Scand J
Immunol 77:389–397. doi:10.1111/sji.12022
28. Lin IC, Kuo HC, Lin YJ, Wang FS, Wang L, Huang SC, Chien SJ,
Huang CF, Wang CL, Yu HR, Chen RF, Yang KD (2012)
Augmented TLR2 expression on monocytes in both human
Kawasaki disease and a mouse model of coronary arteritis. PLoS
One 7:e38635. doi:10.1371/journal.pone.0038635
29. Unizony S, Stone JH, Stone JR (2013) New treatment strate-
gies in large-vessel vasculitis. Curr Opin Rheumatol 25:3–9.
doi:10.1097/BOR.0b013e32835b133a
30. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A,
Dardani L, Pulsatelli L, Meliconi R, Boiardi L (2012)
Tocilizumab: a novel therapy for patients with large-vessel vascu-
litis. Rheumatology (Oxford) 51:151–156. doi:10.1093/
rheumatology/ker296
31. Schäfer VS, Zwerina J (2012) Biologic treatment of large-vessel
vasculitides. Curr Opin Rheumatol 24:31–37. doi:10.1097/BOR.
0b013e32834dc392
32. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S,
Khosroshahi A, Keroack B, Stone JR, Stone JH (2012)
Tocilizumab for the treatment of large-vessel vasculitis (giant cell
arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis
Care Res (Hoboken) 64:1720–1729. doi:10.1002/acr.21750
33. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F,
Villiger PM (2011) Rapid induction of remission in large vessel
vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:
w13156. doi:10.4414/smw.2011.13156
34. Shapiro LS, Farrell J, Borhani Haghighi A (2012) Tocilizumab
treatment for neuro-Behçet’s disease, the first report. Clin Neurol
Neurosurg 114:297–298. doi:10.1016/j.clineuro.2011.10.024
35. Addimanda O, Pipitone N, Pazzola G, Salvarani C (2015)
Tocilizumab for severe refractory neuro-Behcet: three cases IL-6
blockade in neuro-Behcet. Semin Arthritis Rheum 44:472–475.
doi:10.1016/j.semarthrit.2014.08.004
36. Oliveira F, Butendieck RR, Ginsburg WW, Parikh K, Abril A
(2014) Tocilizumab, an effective treatment for relapsing giant cell
arteritis. Clin Exp Rheumatol 32:S76–S78
37. Kieffer P, Hinschberger O, Ciobanu E, Jaeger-Bizet F, Drabo A,
Mostoufizadeh T, Martzolff L (2014) Clinical and biological effi-
cacy of tocilizumab in giant cell arteritis: report of three patients and
literature review. Rev Med Interne 35:56–59. doi:10.1016/j.
revmed.2012.12.012
38. Loricera J, Blanco R, Hernández JL, Castañeda S, Humbría A,
Ortego N, Bravo B, Freire M, Melchor S, Mínguez M, Salvatierra
J, González-Vela C, Calvo-Río V, Santos-Gómez M, Pina T,
González-Gay MA (2016) Tocilizumab in patients with Takayasu
arteritis: a retrospective study and literature review. Clin Exp
Rheumatol 34(3 Suppl 97):S44–S53
39. Ferfar Y, Mirault T, Desbois AC, Comarmond C, Messas E, Savey
L, Domont F, Cacoub P, Saadoun D (2016) Biotherapies in large
vessel vasculitis. Autoimmun Rev 15:544–551. doi:10.1016/j.
autrev.2016.02.012
40. Pazzola G, Muratore F, Pipitone N, Salvarani C (2015) Biologics in
vasculitides: where do we stand, where do we go from now? Presse
Med 44:e231–e239. doi:10.1016/j.lpm.2015.04.010
41. Sifuentes Giraldo WA, Ahijón Lana M, García Villanueva MJ,
González García C, Vázquez Diaz M (2012) Chilblain lupus in-
duced by TNF-α antagonists: a case report and literature review.
Clin Rheumatol 31:563–568. doi:10.1007/s10067-011-1924-x
42. Judson MA (2011) Successful treatment of lupus pernio with
adalimumab. Arch Dermatol 147:1332–1333. doi:10.1001/
archdermatol.2011.307
Clin Rheumatol
